Document Type : systematic review


1 Department of Traditional Medicine, School of Traditional Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

2 Department of Traditional Medicine, School of Traditional Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

3 Department of Pediatrics Pulmonary Diseases, Mofid Children’s Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

4 Department of Epidemiology, University of Tehran, Tehran, Iran.


Background: Cystic fibrosis (CF) is the most common life-threatening hereditary disease among Caucasian populations. Due to the side effects caused by this disease and the high amount of drugs used by the affected patients, performing extensive research seems necessary to find the treatments with greater effectiveness and fewer side effects. The use of Complementary and Alternative Medicine (CAM) is common in both developing and developed countries, but currently available studies performed on the effectiveness of CAM on improving symptoms and reducing complications of CF patients are very limited.
Objective: This systematic review was performed to evaluate the effects of CAM therapies on patients with CF.
Methods: Six credible medical databases (including Cochrane, Science Direct, Embase, ISI, PubMed, and Scopus) were investigated from the beginning of 2000 to the end of 2020, in order to find relevant English-language publications.
Results: From among 1213 articles screened, 57 studies with 2525 patients were included in this study. These articles were then sub-grouped into four categories, including ‘acupuncture’, ‘body techniques’, ‘dietary supplements/nutrition/diet’, and ‘herbal medicine’.
The articles evaluating one of the four parameters of quality of life, pain, pulmonary function, or body mass index were included to be evaluated.
Conclusion: Although we have not evaluated all the studies in the field of the effect of complementary medicine on CF, the review consisting of a large number of these articles showed that despite the great potential of complementary and alternative medicines in this field, extensive research is still needed in this regard.



Cystic Fibrosis (CF) is an autosomal hereditary disease caused by some mutations in the Cystic Fibrosis Transmembrane conductance Regulator (CFTR) gene, which is known as a cAMP-regulated chloride channel expressed in several epithelia (1).

The incidence of CF is reported as 1 in 3500 newborns among Caucasian ethnicity (2). As well, it is considered as a common disease with 80,000 cases worldwide, 30,000 of which are living in the USA (3).

Multiple organ systems, including sinopulmonary, gastrointestinal, endocrine, and genitourinary are affected by CF (4). Respiratory symptoms are also observed in over 90% of CF patients. Correspondingly, these manifestations include pertussis-like cough, repeated episodes of bronchiolitis or obstructive bronchitis, recurrent bronchopneumonia, and pulmonary atelectasis (4). Additionally, Sinus disease is very prevalent in CF, involving chronic sinusitis with an increased prevalence rate of nasal polyps (3).

In this regard, other clinical manifestations of this disease are exocrine pancreatic insufficiency, meconium ileus, episodes of bowel obstruction due to the thickened mucus, intussusception, and intestinal volvulus. Furthermore, cholestasis, liver steatosis, focal biliary cirrhosis, multilobular biliary cirrhosis, portal hypertension, and Cholelithiasis can also be seen in the affected patients (5).

The diagnosis of CF is performed based on the results of two positive sweat tests (dosage of chloride in sweat exceeding 60 mEq/L) or molecular genetic analysis of positive CFTR mutations (2 mutations). Additionally, a high level of immunoreactive serum trypsinogen (IRT) is considered in confirming the diagnosis of CF (4, 5).

Despite some decades of research, there is no definitive treatment for CF yet (6). In general, the effective drugs on controlling CF are the followings: adrenergic receptor agonists, NSAIDs, antibiotics, inhaled corticosteroids, leukotriene inhibitors, inhaled anticholinergics, Dornase alpha, and Ivacaftor (7).

Although CF has a low incidence, it has some potentially significant economic effects on health care resources and other social costs, as well as a significant effect on patients' health-related quality of life (HRQOL) (8). The average annual cost listed for this disease was estimated to be about €44,585 per CF patient in 2017 (9)

Due to the lack of definite treatments proposed for CF, the chronic nature of the disease, high treatment costs, and low quality of life, the essence of complementary and alternative medicines (CAM) becomes more apparent.

CAM was previously defined by the National Centre for Complementary and Alternative Medicine as “health care approaches developed outside of mainstream Western, or conventional medicine used for specific conditions or overall well-being” (10).

Some studies have also shown that the prevalence rate of the CAM use in children with CF is ranged from about 45% to 75% (11-13).

To the best of our knowledge, never before has there any systematic review been conducted about the effect of CAM on CF. As a result, this study aimed to assess the clinical trials investigating the effects of CAM on CF.


The present study was conducted in terms of the ‘Preferred Reporting Items for Systematic reviews and Meta-Analyses’ (PRISMA) guidelines for systematic reviews incorporating a network meta-analysis (14).

The current study was a systematic review of clinical trials conducted on the effects of CAM on CF.

Along with the keyword of “cystic fibrosis”, the literature search included the following keywords for “complementary and alternative medicine”: complementary medicine, alternative medicine, complementary and alternative medicines, herb, plant, extract, diet, dietary supplements, vitamins, acupuncture, relaxation, Mind-body, homeopathy, Ayurveda, traditional Chinese medicine, music, chiropractic, massage, art therapy, aromatherapy, yoga, tai-chi, Religious, and spiritual. Finally, those keywords related to clinical trials were the following: randomized controlled trials (RCTs), randomized clinical trials, randomized clinical trial allocating, single-blind method, cross-over studies, and double-blind method. These investigations were performed in databases of Cochrane, science direct, Embase, ISI, PubMed, and Scopus. To fulfill our purpose, we included English studies published from the beginning of 2000 to the end of 2020. First, two reviewers independently assessed all the studies which met inclusion criteria for the review, during which the title and the abstracts of articles were screened. In the second stage, those studies that seemed relevant were extracted and evaluated in full text. Any disagreement was judged by the third reviewer.

2-1. Inclusion criteria

At this stage, we included all the clinical trials RCTs, uncontrolled trials, and pilot studies that evaluated the effect of any kind of CAM therapies on CF. Thereafter, we set four main parameter measurements as the criteria used for choosing the articles, including quality of life, pulmonary function, body mass index, and pain. These parameters were mentioned more prominently in these studies.  Another inclusion criterion was the articles’ being published in English language from beginning of 2000 to the end of 2020 with no limitation in participants’ age or country.

2-2. Exclusion criteria

After reviewing the full text of the included articles, those that did not measure at least one of the above-mentioned four parameters were excluded.

Considering the methodology of the studies, non-clinical trials, including reviews, cross sectional studies, cohort studies, case series, case reports, animal studies, and in-vitro studies, were excluded.

In regard to the type of the articles, editorial letters, conference papers, posters, and all the publications before 2000 were excluded as well.

2-3. Bias assessment

The Cochrane Collaboration tool was then used for assessing the risk of bias (14). In addition, the full text of the reviewed articles and their protocols, if available, were assessed for finding the appropriateness of their content. Afterward, all the main texts were reviewed and then assessed by an epidemiologist collaboration. According to the Cochrane risk of bias tool, items of random sequence generation, allocation concealment, blinding the participants and personnel, blinding outcome’s assessment, incomplete outcome data, selective reporting, and other sources of bias were assessed.


In the initial phase of search, 1213 articles were found, of which 562 articles remained after removing the duplicates from the title. Subsequently, 434 articles were removed after reviewing the abstracts of the included articles (due to the following reasons: 93 articles had unrelated contents, 220 of them were not clinical trials, 95 studies were In vitro studies, and 26 articles were Animal studies). Finally, 128 articles were selected, of which after reviewing the full text of the studies, 71 did not pass our conditions to be included in the examination of ‘the four parameters’, so they were deleted subsequently. By applying all these criteria, 57 articles remained for the main analysis. The detailed flow diagram of the study is shown in Fig. 1.

The characteristics of these 57 studies and the bias assessment results are summarized in Table 1, 2, and 3. The interventions were divided into four groups, including 1 article in ‘acupuncture’, 10 articles in ‘body techniques’, 45 articles in ‘dietary supplements/nutrition/diet’, and 1 article in ‘herbal medicine’.

The use of body techniques, including Osteopathic manipulative treatment (OMT), summer camp (SC), tai chi (TAI), exercise, massage, yoga, and physiotherapy and massage (PHAM), was also investigated.

It is noteworthy that those articles on dietary supplements/Nutrition/diet evaluated b-carotene, lipid matrix, micronutrients, probiotics, whey protein, growth hormone, magnesium, omega-3, vitamin D, docosahexaenoic acid, Liprotamase, choline, bisphosphonates, Melatonin, antioxidant, creatine supplementation, Megestrol Acetate, protein-energy supplements, N-acetylcysteine, and zinc.

In this phase, 39 articles (68.42%) were found to be randomized and 18 (31.57%) were non-randomized. Moreover, 27 articles (47.36%) had a placebo group and 30 (52.63%) of them had no placebo group. The reviewed studies were conducted in Australia, Austria, Belgium, Brazil, Canada, Denmark, England, Germany, India, Iran, Israel, Italy, Netherlands, Spain, Sweden, Switzerland, Turkey, The United Kingdom (UK), and The United States of America (USA).


This systematic review highlights the fact that despite the high necessity and high capacity, just a few studies have been performed on the effect of CAM on CF, and as a result, there is insufficient clinical evidence for a perfect assessment. The use of traditional medicine has been indicated to have some positive effects on various aspects of CF patients. Nevertheless, due to the large number of investigated parameters and their dispersion, we only evaluated 4 items in this study.

We found one article in acupuncture, 10 articles in Body techniques, 46 articles in Dietary supplements/Nutrition/diet, and one article in Herbal medicine (garlic). Allium sativum (garlic) has been found to have immunomodulatory, antimicrobial, antiviral, and anti-inflammatory properties. Additionally, it has the ability of reducing the expression of proinflammatory cytokines (72).

Smyth et al. (2010) in their pilot study, evaluated the effect of garlic on CF patients. In this study, the mean (±SD) of increase in weight, change from baseline FEV1, and modification in clinical score were greater with garlic compared to those of placebo; however, they were non-significant (24). This can be due to the limited sample size of the study, so it is recommended to be reviewed in more extensive clinical trials.

Different kinds of pain, including back pain, chest pain, and headache, were commonly seen among CF patients (19). These pains reduce the quality of life of these patients and are also associated with pulmonary exacerbations (73). Yuan-Chi Lin et al. (2005) measured the effect of acupuncture on pain management and achieved positive results (21).

Body techniques including Osteopathic manipulative treatment, summer camp, tai chi, exercise, yoga, physiotherapy, and massage were also applied. Notably, CF patients are at a higher risk of getting airway infections compared to the general population. Exercise can play important and key roles in improving the process of clearing lung secretions and reducing inflammation (74). Sumita Gupta et al. (2019) also found that exercise programs are not correlated with a significant improvement in bone marrow density (BMD) of CF patients, but it had a positive effect on both physical and mental health statuses of these patients (18). In another study, H.C.Selvadurai et al. found that the patients receiving aerobic training had significantly higher levels of peak aerobic capacity, activity levels, and quality of life compared to the control group (23).

Some beneficial effects of the dietary supplements and nutrition were also observed on the CF patients. Hanssens et al., for instance, examined the effects of long-term omega-3 supplementation on the number of exacerbations as well as the duration of antibiotic therapy in CF patients, and found several clinical benefits as a result (36). In another study, it was shown to have some positive effects like decreasing inflammation (49). Beta carotene was also found to have significant effects on pulmonary function and quality of life in CF patients (27, 28). Whey proteins were, further, indicated to improve nutritional status and they have additional beneficial effects on inflammation in patients with CF. They also appear to have several potential immune-modulating effects that can be beneficial for CF patients over the long term (33).

Vitamin D supplementation may contribute to reduced inflammation and improved lung function in CF. It was found to be positively correlated with some changes in the adult Quality-of-Life respiratory score at the end of the supplementation (65).

The articles that examined the effect of antioxidants on CF manifested some improvements in the paitioents’ weight and pulmonary function (50, 51, 66, 69). It was also demonstrated that an antioxidant cocktail can improve vascular endothelial function and oxidative stress in patients with CF, providing evidence that oxidative stress is a key contributor to vascular endothelial dysfunction in CF (69).

Moreover, the use of low-dose supplements of fatty acids over a long period (one year) appeared to improve pulmonary function, as well as the inflammatory and anthropometric parameters in adults with CF (61).

Likewise, The effects of zinc supplementation on CF patients showed good results, including significant increases in both height and weight and a decrease in the number of hospitalizations (63).


Although there is a great potential for using CAM techniques to manage cystic fibrosis, very limited evidence exists to support the use of CAM in the treatment of CF. Despite its widespread administration, such routine use cannot be supported by the existing research evidence; and more accurate data are required.


Some of the articles studied in this systematic review had a low methodological quality. Other limitations include high heterogeneity of the studies, resulting from the variety in the types of CAM therapies; and the small sample sizes in most articles indicating the need for further studies with larger sample sizes in this regard.




This paper was conducted based on the PhD thesis of Dr. Samira Borhani (MD) entitled "The Effect of Compound Honey Syrup on Clinical Manifestations of Chronic Sinusitis in Cystic Fibrosis (CF) Patients", registered with number 222 (Pajoohan code 01-22717) in Department of Traditional Medicine, School of Traditional Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.


    1. Braga SFF, Almgren MM. Complementary therapies in cystic fibrosis: Nutritional supplements and herbal products. Journal of Pharmacy Practice2013. p. 14-7.
    2. Cronly J, Duff A, Riekert K, Horgan A, Lehane E, Perry I, et al. Positive mental health and wellbeing in adults with cystic fibrosis: A cross sectional study. Journal of Psychosomatic Research: Elsevier; 2019. p. 125-30.
    3. Young TJ, Li DA, Eshaghian PH. Cystic Fibrosis: an Update on Disease Pathophysiology, Management, and Novel Modalities of Therapy. Current Treatment Options in Allergy: Current Treatment Options in Allergy; 2019. p. 226-37.
    4. Note I. Cystic fibrosis - management Cystic fibrosis - management. 2010. p. 1-11.
    5. Dos Santos ALM, Santos HdM, Nogueira MB, Távora HTO, da Cunha MdLJP, Seixas RBPdM, Velloso Monte LDF, Carvalho ED. Cystic fibrosis: Clinical phenotypes in children and adolescents. Pediatric Gastroenterology, Hepatology and Nutrition2018. p. 306-14.
    6. Denford S, Van Beurden S, O'Halloran P, Williams CA. Barriers and facilitators to physical activity among children, adolescents, and young adults with cystic fibrosis: A systematic review and thematic synthesis of qualitative research. BMJ Open2020.
    7. Mogayzel PJ, Naureckas ET, Robinson KA, Mueller G, Hadjiliadis D, Hoag JB, Lubsch L, Hazle L, Sabadosa K, Marshall B. Cystic fibrosis pulmonary guidelines: Chronic medications for maintenance of lung health. American Journal of Respiratory and Critical Care Medicine2013. p. 680-9.
    8. Angelis A, Kanavos P, López-Bastida J, Linertová R, Nicod E, Serrano-Aguilar P. Social and economic costs and health-related quality of life in non-institutionalised patients with cystic fibrosis in the United Kingdom. BMC Health Services Research: BMC Health Services Research; 2015. p. 1-8.
    9. Durieu I, Dalon F, Reynaud Q, Lemonnier L, Dehillotte C, Berard M, Walther D, Viprey M, Van Ganse E, Belhassen M. Temporal trends in healthcare resource use and associated costs of patients with cystic fibrosis. J Cyst Fibros. 2021.
    10. Y. Ng J, Nazir Z, Nault H. Complementary, Alternative, or Integrative Health: What’s In a Name? National Institutes of Health, National Centre for Complementary. BMC Complementary Medicine and Therapies (2020) 20:299 Page 13 of 15 and Integrative Health (NCCIH).
    11. Giangioppo S, Kalaci O, Radhakrishnan A, Fleischer E, Itterman J, Lyttle B, Price A, Radhakrishnan D. Complementary and alternative medicine use in children with cystic fibrosis. Complementary Therapies in Clinical Practice: Elsevier Ltd; 2016. p. 68-74.
    12. Tanase A, Zanni R. The use of complementary and alternative medicine among pediatric cystic fibrosis patients. Journal of Alternative and Complementary Medicine2008. p. 1271-3.
    13. Richmond E, Adams D, Dagenais S, Clifford T, Baydala L, James King W, Vohra S. Complementary and alternative medicine: A survey of its use in children with chronic respiratory illness. Canadian Journal of Respiratory Therapy 2015. p. 27-32.
    14. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. BMJ (Online) 2009. p. 332-6.
    15. Swender DA, Thompson G, Schneider K, McCoy K, Patel A. Osteopathic manipulative treatment for inpatients with pulmonary exacerbations of cystic fibrosis: Effects on spirometry findings and patient assessments of breathing, anxiety, and pain. Journal of the American Osteopathic Association2014. p. 450-8.
    16. Blau H, Mussaffi-Georgy H, Fink G, Kaye C, Szeinberg A, Spitzer SA, Spitzer SA, Yahav J. Effects of an intensive 4-week summer camp on cystic fibrosis: Pulmonary function, exercise tolerance, and nutrition. Chest: The American College of Chest Physicians; 2002. p. 1117-22.
    17. Carr SB, Ronan P, Lorenc A, Mian A, Madge SL, Robinson N. Children and Adults Tai Chi Study (CF-CATS2): a randomized controlled feasibility study comparing internet-delivered with face-to-face Tai Chi lessons in cystic fibrosis. ERJ Open Research2018. p. 00042-2018.
    18. Gupta S, Mukherjee A, Lodha R, Kabra M, Deepak KK, Khadgawat R, Talwar A, Kabra SK. Effects of Exercise Intervention Program on Bone Mineral Accretion in Children and Adolescents with Cystic Fibrosis: A Randomized Controlled Trial. Indian Journal of Pediatrics: The Indian Journal of Pediatrics; 2019. p. 987-94.
    19. Hubert D, Soubeiran L, Gourmelon F, Grenet D, Serreau R, Perodeau E, Zegarra-Parodi R, Boutron I. Impact of osteopathic treatment on pain in adult patients with cystic fibrosis - A pilot randomized controlled study. PLoS ONE 2014.
    20. Zink KK, Chini B, Cowens J, Kremer L, Lin L. Improving clinical outcomes and quality of life with massage therapy in youth and young adults with cystic fibrosis: A pilot study. International Journal of Therapeutic Massage and Bodywork: Research, Education, and Practice2019. p. 4-15.
    21. Lin YC, Ly H, Golianu B. Acupuncture pain management for patients with cystic fibrosis: A pilot study. American Journal of Chinese Medicine2005. p. 151-6.
    22. Ruddy J, Emerson J, Mcnamara S, Genatossio A, Breuner C, Weber T, Rosenfeld M. Yoga as a Therapy for Adolescents and Young Adults with Cystic Fibrosis: A Pilot Study. Global Advances in Health and Medicine 2015. p. 32-6.
    23. Selvadurai HC, Blimkie CJ, Meyers N, Mellis CM, Cooper PJ, Van Asperen PP. Randomized controlled study of in-hospital exercise training programs in children with cystic fibrosis. Pediatric Pulmonology2002. p. 194-200.
    24. Smyth AR, Cifelli PM, Ontario CA, Righetti K, Lewis S, Erskine P, Holland ED, Givskov M, Williams P, Cámara M, Barrett DA, Knox A. Garlic as an inhibitor of Pseudomonas aeruginosa quorum sensing in cystic fibrosis-a pilot randomized controlled trial Pediatric Pulmonology 2010. p. 356-62.
    25. Mcnamara C, Johnson M, Read L, Velden HV, Thygeson M, Liu M, Gandrud L, McNamara J. Yoga therapy in children with cystic fibrosis decreases immediate anxiety and joint pain. Evidence-based Complementary and Alternative Medicine2016.
    26. Lee A, Holdsworth M, Holland A, Button B. The immediate effect of musculoskeletal physiotherapy techniques and massage on pain and ease of breathing in adults with cystic fibrosis. Journal of Cystic Fibrosis: Elsevier B.V.; 2009. p. 79-81.
    27. Çobanoǧlu N, Özçelik U, Göçmen A, Kiper N, Doǧru D. Antioxidant effect of β-carotene in cystic fibrosis and bronchiectasis: Clinical and laboratory parameters of a pilot study. Acta Paediatrica, International Journal of Paediatrics2002. p. 793-8.
    28. Rust P, Eichler I, Renner S, Elmadfa I. Long-term oral β-carotene supplementation in patients with cystic fibrosis - Effects on antioxidative status and pulmonary function. Annals of Nutrition and Metabolism2000. p. 30-7.
    29. Renner S, Rath R, Rust P, Lehr S, Frischer T, Elmadfa I, Eichler I. Effects of β-carotene supplementation for six months on clinical and laboratory parameters in patients with cystic fibrosis. Thorax2001. p. 48-52.
    30. Groleau V, Schall JI, Dougherty KA, Latham NE, Maqbool A, Mascarenhas MR, Stallings VA. Effect of a dietary intervention on growth and energy expenditure in children with cystic fibrosis. Journal of Cystic Fibrosis: European Cystic Fibrosis Society, 2014. p. 572-8.
    31. Oudtshoorn JH, Klein PHC, Hoffman Z, Voorbij HAM, van der Ent CK, Berger R. Dietary supplementation with multiple micronutrients: No beneficial effects in pediatric cystic fibrosis patients. Journal of Cystic Fibrosis 2007. p. 35-40.
    32. Weiss B, Bujanover Y, Yahav Y, Vilozni D, Fireman E, Efrati O. Probiotic supplementation affects pulmonary exacerbations in patients with cystic fibrosis: A pilot study. Pediatric Pulmonology2010. p. 536-40.
    33. Lands LC, Iskandar M, Beaudoin N, Meehan B, Dauletbaev N, Berthiuame Y. Dietary supplementation with pressurized whey in patients with cystic fibrosis. Journal of Medicinal Food2010. p. 77-82.
    34. Hardin DS, Rice J, Ahn C, Ferkol T, Howenstine M, Spears S, Prestidge C, Seilheimer DK, Shepherd R. Growth hormone treatment enhances nutrition and growth in children with cystic fibrosis receiving enteral nutrition. Journal of Pediatrics2005. p. 324-8.
    35. Gontijo-Amaral C, Guimarães EV, Camargos P. Oral magnesium supplementation in children with cystic fibrosis improves clinical and functional variables: A double-blind, randomized, placebo-controlled crossover trial. American Journal of Clinical Nutrition2012. p. 50-6.
    36. Hanssens L, Thiébaut I, Lefèvre N, Malfroot A, Knoop C, Duchateau J, Casimir G. The clinical benefits of long-term supplementation with omega-3 fatty acids in cystic fibrosis patients - A pilot study. Prostaglandins Leukotrienes and Essential Fatty Acids: Elsevier; 2016. p. 45-50.
    37. Grey V, Mohammed SR, Smountas AA, Bahlool R, Lands LC. Improved glutathione status in young adult patients with cystic fibrosis supplemented with whey protein. Journal of Cystic Fibrosis2003. p. 195-8.
    38. Skov M, Pressler T, Lykkesfeldt J, Poulsen HE, Jensen PØ, Johansen HK, Qvist T, Kræmer D, Høiby N, Ciofu O. The effect of short-term, high-dose oral N-acetylcysteine treatment on oxidative stress markers in cystic fibrosis patients with chronic P. aeruginosa infection - A pilot study. Journal of Cystic Fibrosis: European Cystic Fibrosis Society; 2015. p. 211-8.
    39. Bilan N, Marefat E, Nouri-Vaskeh M, Nikniaz L, Nikniaz Z. Effects of synbiotic supplementation on the pulmonary manifestations and anthropometric measurements in children with cystic fibrosis- a randomized clinical trial. European Journal of Integrative Medicine: Elsevier; 2020. p. 101027.
    40. Van Biervliet S, Hauser B, Verhulst S, Stepman H, Delanghe J, Warzee JP, Pot B, Vandewiele T, Wilschanski M. Probiotics in cystic fibrosis patients: A double blind crossover placebo controlled study: Pilot study from the ESPGHAN Working Group on Pancreas/CF. Clinical Nutrition ESPEN: Elsevier Ltd; 2018. p. 59-65.
    41. De Alessandri A, Minicucci L, Buzzetti R, Zucchi C, Ierardi MP, Casciaro R, Perri K, Cresta F, Iorio EL. Low-dose whey proteins supplementation can reduce oxidative stress in Cystic Fibrosis. A 36 months preliminary clinical trial. Progress in Nutrition 2011. p. 71-80.
    42. Abu-Fraiha Y, Elyashar-Earon H, Shoseyov D, Cohen-Cymberknoh M, Armoni S, Kerem E, Wilschanski M. Increasing Vitamin D Serum Levels Is Associated with Reduced Pulmonary Exacerbations in Patients with Cystic Fibrosis. Journal of Pediatric Gastroenterology and Nutrition 2019. p. 110-5.
    43. Alicandro G, Faelli N, Gagliardini R, Santini B, Magazzù G, Biffi A, Risé P, Galli C, Tirelli AS, Loi S, Valmarana L, Cirilli N, Palmas T, Vieni G, Bianchi ML, Agostoni C, Colombo C. A randomized placebo-controlled study on high-dose oral algal docosahexaenoic acid supplementation in children with cystic fibrosis. Prostaglandins Leukotrienes and Essential Fatty Acids2013. p. 163-9.
    44. Borowitz D, Stevens C, Brettman LR, Campion M, Wilschanski M, Thompson H. Liprotamase long-term safety and support of nutritional status in pancreatic-insufficient cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2012. p. 248-57.
    45. Bernhard W, Lange R, Graepler-Mainka U, Engel C, Machann J, Hund V, Shunova A, Hector A, Riethmüller J. Choline supplementation in cystic fibrosis— The metabolic and clinical impact. Nutrients2019.
    46. Conway SP, Oldroyd B, Morton A, Truscott JG, Peckham DG. Effect of oral bisphosphonates on bone mineral density and body composition in adult patients with cystic fibrosis: A pilot study. Thorax2004. p. 699-703.
    47. De Castro-Silva C, De Bruin VMS, Cunha GMA, Nunes DM, Medeiros CAM, De Bruin PFC. Melatonin improves sleep and reduces nitrite in the exhaled breath condensate in cystic fibrosis - A randomized, double-blind placebo-controlled study. Journal of Pineal Research2010. p. 65-71.
    48. De Freitas MB, Moreira EAM, Oliveira DDL, Tomio C, Da Rosa JS, Moreno YMF, Barbosa E, Neto NL, Buccigrossi V, Guarino A, Fröde TS. Effect of synbiotic supplementation in children and adolescents with cystic fibrosis: A randomized controlled clinical trial. European Journal of Clinical Nutrition2018. p. 736-43.
    49. De Vizia B, Raia V, Spano C, Pavlidis C, Coruzzo A, Alessio M. Effect of an 8-month treatment with ω-3 fatty acids (eicosapentaenoic and docosahexaenoic) in patients with cystic fibrosis. Journal of Parenteral and Enteral Nutrition2003. p. 52-7.
    50. Wood LG, Fitzgerald DA, Lee AK, Garg ML. Improved antioxidant and fatty acid status of patients with cystic fibrosis after antioxidant supplementation is linked to improved lung function. American Journal of Clinical Nutrition2003. p. 150-9.
    51. Sagel SD, Sontag MK, Anthony MM, Emmett P, Papas KA. Effect of an antioxidant-rich multivitamin supplement in cystic fibrosis. Journal of Cystic Fibrosis: European Cystic Fibrosis Society, 2011. p. 31-6.
    52. Braegger CP, Schlattner U, Wallimann T, Utiger A, Frank F, Schaefer B, Heizmann CW, Sennhauser FH. Effects of creatine supplementation in cystic fibrosis: Results of a pilot study. Journal of Cystic Fibrosis2003. p. 177-82.
    53. Jumpsen JA, Brown NE, Thomson ABR, Paul Man SF, Goh YK, Ma D, et al. Fatty acids in blood and intestine following docosahexaenoic acid supplementation in adults with cystic fibrosis. Journal of Cystic Fibrosis2006. p. 77-84.
    54. Jafari SA, Mehdizadeh-Hakkak A, Kianifar HR, Hebrani P, Ahanchian H, Abbasnejad E. Effects of probiotics on quality of life in children with cystic fibrosis; A randomized controlled trial. Iranian Journal of Pediatrics2013. p. 669-74.
    55. Kanhere M, Chassaing B, Gewirtz AT, Tangpricha V. Role of vitamin D on gut microbiota in cystic fibrosis. Journal of Steroid Biochemistry and Molecular Biology: Elsevier Ltd; 2018. p. 82-7.
    56. Keen C, Olin AC, Eriksson S, Ekman A, Lindblad A, Basu S, Beermann C, Strandvik B. Supplementation with fatty acids influences the airway nitric oxide and inflammatory markers in patients with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2010. p. 537-44.
    57. Leonard A, Davis E, Rosenstein BJ, Zeitlin PL, Paranjape SM, Peeler D, Maynard C, Mogayzel PJ. Description of a standardized nutrition classification plan and its relation to nutritional outcomes in children with cystic fibrosis. Journal of Pediatric Psychology2010. p. 6-13.
    58. Lloyd-Still JD, Powers CA, Hoffman DR, Boyd-Trull K, Lester LA, Benisek DC. Bioavailability and safety of a high dose of docosahexaenoic acid triacylglycerol of algal origin in cystic fibrosis patients: A randomized, controlled study. Nutrition2006. p. 36-46.
    59. Marchand V, Baker SS, Stark TJ, Baker RD. Randomized, double-blind, placebo-controlled pilot trial of megestrol acetate in malnourished children with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2000. p. 264-9.
    60. Tangpricha V, Lukemire J, Chen Y, Binongo JNG, Judd SE, Michalski ES, Lee MJ, Walker S, Ziegler TR, Tirouvanziam R, Zughaier SM, Chesdachai S, Hermes WA, Chmiel JF, Grossmann RE, Gaggar A, Joseph PM, Alvarez JA. Vitamin D for the Immune System in Cystic Fibrosis (DISC): A double-blind, multicenter, randomized, placebo-controlled clinical trial. American Journal of Clinical Nutrition: Oxford University Press; 2019. p. 554-65.
    61. Olveira G, Olveira C, Acosta E, Espíldora F, Garrido-Sánchez L, García-Escobar E, Rojo-Martíneza G, Gonzaloa M, Soriguera F. Fatty Acid Supplements Improve Respiratory, Inflammatory and Nutritional Parameters in Adults with Cystic Fibrosis. Archivos de Bronconeumologia: Elsevier; 2010. p. 70-7.
    62. Poustie VJ, Russell JE, Watling RM, Ashby D, Smyth RL. Oral protein energy supplements for children with cystic fibrosis: CALICO multicentre randomized controlled trial. British Medical Journal2006. p. 632-5.
    63. Ataee P, Najafi M, Gharagozlou M, Aflatounian M, Mahmoudi M, Khodadad A, Farahmand F, Motamed F, Fallahi GH, Kalantari N, Soheili H, Modarresi V, Sabbaghian Modarresi M, Rezaei N. Effect of supplementary zinc on body mass index, pulmonary function and hospitalization in children with cystic fibrosis. Turkish Journal of Pediatrics2014. p. 127-32.
    64. Grossmann RE, Zughaier SM, Kumari M, Seydafkan S, Lyles RH, Liu S, Sueblinvong V, Schechter MS, Stecenko AA, Ziegler TR, Tangpricha V. Pilot study of vitamin D supplementation in adults with cystic fibrosis pulmonary exacerbation: A randomized, controlled trial. Dermato-Endocrinology2012. p. 191-7.
    65. Pincikova T, Paquin-Proulx D, Sandberg JK, Flodström-Tullberg M, Hjelte L. Clinical impact of Vitamin D treatment in cystic fibrosis: A pilot randomized, controlled trial. European Journal of Clinical Nutrition2017. p. 203-5.
    66. Sagel SD, Khan U, Jain R, Graff G, Daines CL, Dunitz JM, Borowitz D, Orenstein DM, Abdulhamid I, Noe J, Clancy JP, Slovis B, Rock MJ, McCoy KS, Strausbaugh S, Livingston FR, Papas KA, Shaffer ML. Effects of an antioxidant-enriched multivitamin in cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2018. p. 639-47.
    67. Schall JI, Mascarenhas MR, Maqbool A, Dougherty KA, Elci O, Wang DJ, Altes TA, Hommel KA, Shaw W, Moore J, Stallings VA. Choline supplementation with a structured lipid in children with cystic fibrosis: A randomized placebo-controlled trial. Journal of Pediatric Gastroenterology and Nutrition2016. p. 618-26.
    68. Steinkamp G, Demmelmair H, Rühl-Bagheri I, Von Der Hardt H, Koletzko B. Energy supplements rich in linoleic acid improve body weight and essential fatty acid status of cystic fibrosis patients. Journal of Pediatric Gastroenterology and Nutrition2000. p. 418-23.
    69. Tucker MA, Fox BM, Seigler N, Rodriguez-Miguelez P, Looney J, Thomas J, McKie KT, Forseen C, Davison GW, Harris RA. Endothelial dysfunction in cystic fibrosis: Role of oxidative stress. Oxidative Medicine and Cellular Longevity2019.
    70. Van Biervliet S, Devos M, Delhaye T, Van Biervliet JP, Robberecht E, Christophe A. Oral DHA supplementation in ΔF508 homozygous cystic fibrosis patients. Prostaglandins Leukotrienes and Essential Fatty Acids2008. p. 109-15.
    71. Sharma G, Lodha R, Shastri S, Saini S, Kapil A, Singla M, Mukherjee A, Jat KR, Kabra M, Kabra SK. Zinc supplementation for one year among children with cystic fibrosis does not decrease pulmonary infection. Respiratory Care 2016. p. 78-84.
    72. Metin M, Donma O. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID- 19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information 2020.
    73. Havermans T, Colpaert K, De Boeck K, Dupont L, abbott J. Pain in CF: Review of the literature. Journal of Cystic Fibrosis: European Cystic Fibrosis Society. 2013. p. 423-30.
    74. Fernandez-del-Valle M, Donadio MVF, Pérez-Ruiz M. Physical exercise as a tool to minimize the consequences of the Covid-19 quarantine: An overview for cystic fibrosis. Pediatric Pulmonology2020. p. 2877-82.